The immunology of neuromyelitis optica—Current knowledge, clinical implications, controversies and future perspectives

International Journal of Molecular Sciences

Volumn 17, Issue 3, 2016, Pages

  Jasiak Zatonska, Michalina ^a   Kalinowska Lyszczarz, Alicja ^a   Michalak, Slawomir ^a,b   Kozubski, Wojciech ^a  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^b MOSSAKOWSKI MEDICAL RESEARCH CENTRE   (Poland)

Author keywords

Aquaporin 1 antibody (AQP1 Ab); Aquaporin 4 immunoglobulin G (AQP4 IgG); Immunopathogenesis; Myelin oligodendrocyte glycoprotein immunoglobulin G (MOG IgG); Neuroimmunology; Neuromyelitis optica (NMO); Neuromyelitis optica spectrum disorder (NMOsd)

Indexed keywords

AQUAPORIN 1; AQUAPORIN 4; AZATHIOPRINE; CHEMOKINE RECEPTOR CCR3; COMPLEMENT MEMBRANE ATTACK COMPLEX; GRANULOCYTE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN; INTERLEUKIN 17; INTERLEUKIN 6; LEUKOCYTE ELASTASE; MAJOR BASIC PROTEIN; METHYLPREDNISOLONE; MITOXANTRONE; MYCOPHENOLATE MOFETIL; MYELIN OLIGODENDROCYTE GLYCOPROTEIN; PREDNISONE; RITUXIMAB; AUTOANTIBODY; BIOLOGICAL MARKER; IMMUNOGLOBULIN G;

ACUTE DISSEMINATED ENCEPHALOMYELITIS; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; AUTOIMMUNE DISEASE; DISEASE ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; EXPANDED DISABILITY STATUS SCALE; HUMAN; IMMUNE RESPONSE; IMMUNOFLUORESCENCE; IMMUNOGLOBULIN PRODUCTION; IMMUNOLOGY; IMMUNOPATHOGENESIS; MULTIPLE SCLEROSIS; MYASTHENIA GRAVIS; MYELITIS; MYELOOPTIC NEUROPATHY; NERVE CELL DEGENERATION; NUCLEAR MAGNETIC RESONANCE IMAGING; OPTIC NEURITIS; PLASMAPHERESIS; PROTEIN EXPRESSION; RADIOIMMUNOPRECIPITATION; RESPIRATORY FAILURE; REVIEW; SENSITIVITY AND SPECIFICITY; SYSTEMIC LUPUS ERYTHEMATOSUS; ANIMAL; NEUROMYELITIS OPTICA; OPTIC NERVE; PATHOLOGY; SPINAL CORD;

ANIMALS; AQUAPORIN 4; AUTOANTIBODIES; BIOMARKERS; HUMANS; IMMUNOGLOBULIN G; MYELIN-OLIGODENDROCYTE GLYCOPROTEIN; NEUROMYELITIS OPTICA; OPTIC NERVE; SPINAL CORD;

EID: 84959510353     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms17030273     Document Type: Review

References (81)

1. Wingerchuk, D.M.; Hogancamp, W.F.; O’Brien, P.C.; Weinshenker, B.G. The clinical course of neuromyelitis optica (Devic’s syndrome). Neurology 1999, 53, 1107.
2. Wingerchuk, D.M.; Lennon, V.A.; Lucchinetti, C.F.; Pittock, S.J.; Weinshenker, B.G. The spectrum of neuromyelitis optica. Lancet Neurol. 2007, 6, 805–815.
3. Wingerchuk, D.M.; Lennon, V.A.; Pittock, S.J.; Lucchinetti, C.F.; Weinshenker, B.G. Revised diagnostic criteria for neuromyelitis optica. Neurology 2006, 66, 1485–1489.
4. Jarius, S.; Wildemann, B. The history of neuromyelitis optica. J. Neuroinflamm. 2013, 10, 1–12.
5. Lennon, V.A.; Wingerchuk, D.M.; Kryzer, T.J.; Pittock, S.J.; Lucchinetti, C.F.; Fujihara, K.; Nakashima, I.; Weinshenker, B.G. A serum autoantibody marker of neuromyelitis optica: Distinction from multiple sclerosis. Lancet 2004, 364, 2106–2112.
6. Lennon, V.A.; Kryzer, T.J.; Pittock, S.J.; Verkman, A.S.; Hinson, S.R. IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J. Exp. Med. 2005, 202, 473–477.
7. Wingerchuk, D.M. Neuromyelitis spectrum disorders. Contin. Lifelong Learn. Neurol. 2010, 16, 105–121.
8. Wingerchuk, D.M.; Banwell, B.; Bennett, J.L.; Cabre, P.; Carroll, W.; Chitnis, T.; De Seze, J.; Fujihara, K.; Greenberg, B.; Jacob, A.; et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology 2015, 85, 177–189
9. Papadopoulos, M.C.; Verkman, A.S. Aquaporin 4 and neuromyelitis optica. Lancet Neurol. 2012, 11, 535–544
10. Matiello, M.; Kim, H.J.; Kim, W.; Brum, D.G.; Barreira, A.A.; Kingsbury, D.J.; Plant, G.T.; Adoni, T.; Weinshenker, B.G. Familial neuromyelitis optica. Neurology 2010, 75, 310–315
11. Tzartos, J.S.; Stergiou, C.; Kilidireas, K.; Zisimopoulou, P.; Thomaidis, T.; Tzartos, S.J. Anti-aquaporin-1 autoantibodies in patients with neuromyelitis optica spectrum disorders. PLoS ONE 2013, 8, e74773.
12. Saadoun, S.; Waters, P.; Owens, G.P.; Bennett, J.L.; Vincent, A.; Papadopoulos, M.C. Neuromyelitis optica MOG-IgG causes reversible lesions in mouse brain. Acta Neuropathol. Commun. 2014, 2.
13. Lucchinetti, C.F.; Mandler, R.N.; McGavern, D.; Bruck, W.; Gleich, G.; Ransohoff, R.M.; Trebst, C.; Weinshenker, B.; Wingerchuk, D.; Parisi, J.E.; et al. A role for humoral mechanisms in the pathogenesis of Devic’s neuromyelitis optica. Brain 2002, 125, 1450–1461
14. Saadoun, S.; Waters, P.; MacDonald, C.; Bell, B.A.; Vincent, A.; Verkman, A.S.; Papadopoulos, M.C. Neutrophil protease inhibition reduces neuromyelitis optica-immunoglobulin G-induced damage in mouse brain Ann. Neurol. 2012, 71, 323–333.
15. Hendriks, J.J.; Teunissen, C.E.; de Vries, H.E.; Dijkstra, C.D. Macrophages and neurodegeneration. Brain Res. Rev. 2005, 48, 185–195
16. Bradl, M.; Misu, T.; Takahashi, T.; Watanabe, M.; Mader, S.; Reindl, M.; Adzemovic, M.; Bauer, J.; Berger, T.; Fujihara, K.; et al. Neuromyelitis optica: Pathogenicity of patient immunoglobulin in vivo. Ann. Neurol. 2009, 66, 630–643
17. Segal, B.M. Th17 cells in autoimmune demyelinating disease. Semin. Immunopathol. 2010, 32, 71–77.
18. Wang, H.H.; Dai, Y.Q.; Qiu, W.; Lu, Z.Q.; Peng, F.H.; Wang, Y.G.; Bao, J.; Li, Y.; Hu, X.Q. Interleukin-17-secreting T cells in neuromyelitis optica and multiple sclerosis during relapse. J. Clin. Neurosci. 2011, 18, 1313–1317.
19. Li, Y.; Wang, H.; Long, Y.; Lu, Z.; Hu, X. Increased memory Th17 cells in patients with neuromyelitis optica and multiple sclerosis. J. Neuroimmunol. 2011, 234, 155–160.
20. Ratelade, J.; Zhang, H.; Saadoun, S.; Bennett, J.L.; Papadopoulos, M.C.; Verkman, A.S. Neuromyelitis optica IgG and natural killer cells produce NMO lesions in mice without myelin loss. Acta Neuropathol. 2012, 123, 861–872
21. Chihara, N.; Aranami, T.; Sato, W.; Miyazaki, Y.; Miyake, S.; Okamoto, T.; Ogawa, M.; Toda, T.; Yamamura, T. Interleukin 6 signaling promotes anti-aquaporin 4 autoantibody production from plasmablasts in neuromyelitis optica. Proc. Natl. Acad. Sci. USA 2011, 108, 3701–3706.
22. Bennett, J.L.; Lam, C.; Kalluri, S.R.; Saikali, P.; Bautista, K.; Dupree, C.; Glogowska, M.; Case, D.; Antel, J.P.; Owens, G.P.; et al. Intrathecal pathogenic anti-aquaporin-4 antibodies in early neuromyelitis optica. Ann. Neurol. 2009, 66, 617–629.
23. Nagelhus, E.A.; Ottersen, O.P. Physiological roles of aquaporin-4 in brain. Physiol. Rev. 2013, 93, 1543–1562
24. Ho, J.D.; Yeh, R.; Sandstrom, A.; Chorny, I.; Harries, W.E.; Robbins, R.A.; Miercke, L.J.; Stroud, R.M. Crystal structure of human aquaporin 4 at 1.8 Å and its mechanism of conductance. Proc. Natl. Acad. Sci. USA 2009, 106, 7437–7442.
25. Waters, P.; Vincent, A. Detection of anti-aquaporin-4 antibodies in neuromyelitis optica: Current status of the assays. Int. MS J. 2008, 15, 99–105
26. Nicchia, G.P.; Mastrototaro, M.; Rossi, A.; Pisani, F.; Tortorella, C.; Ruggieri, M.; Lia, A.; Trojano, M.; Frigeri, A.; Svelto, M. Aquaporin-4 orthogonal arrays of particles are the target for neuromyelitis optica autoantibodies. Glia 2009, 57, 1363–1373
27. Crane, J.M.; Lam, C.; Rossi, A.; Gupta, T.; Bennett, J.L.; Verkman, A.S. Binding affinity and specificity of neuromyelitis optica autoantibodies to aquaporin-4 M1/M23 isoforms and orthogonal arrays. J. Biol. Chem. 2011, 286, 16516–16524
28. Phuan, P.-W.; Ratelade, J.; Rossi, A.; Tradtrantip, L.; Verkman, A.S. Complement-dependent cytotoxicity in neuromyelitis optica requires aquaporin-4 protein assembly in orthogonal arrays. J. Biol. Chem. 2012, 287, 13829–13839.
29. Takahashi, T.; Fujihara, K.; Nakashima, I.; Misu, T.; Miyazawa, I.; Nakamura, M.; Watanabe, S.; Shiga, Y.; Kanaoka, C.; Fujimori, J.; et al. Anti-aquaporin-4 antibody is involved in the pathogenesis of NMO: A study on antibody titre. Brain 2007, 130, 1235–1243.
30. Jarius, S.; Aboul-Enein, F.; Waters, P.; Kuenz, B.; Hauser, A.; Berger, T.; Lang, W.; Reindl, M.; Vincent, A.; Kristoferitsch, W. Antibody to aquaporin-4 in the long-term course of neuromyelitis optica. Brain 2008, 131, 3072–3080.
31. Hinson, S.R.; McKeon, A.; Lennon, V.A. Neurological autoimmunity targeting aquaporin-4. Neuroscience 2010, 168, 1009–1018
32. Hinson, S.R.; Roemer, S.F.; Lucchinetti, C.F.; Fryer, J.P.; Kryzer, T.J.; Chamberlain, J.L.; Howe, C.L.; Pittock, S.J.; Lennon, V.A. Aquaporin-4-binding autoantibodies in patients with neuromyelitis optica impair glutamate transport by down-regulating EAAT2. J. Exp. Med. 2008, 205, 2473–2481.
33. Vincent, T.; Saikali, P.; Cayrol, R.; Roth, A.D.; Bar-Or, A.; Prat, A.; Antel, J.P. Functional consequences of neuromyelitis optica-IgG astrocyte interactions on blood-brain barrier permeability and granulocyte recruitment. J. Immunol. 2008, 181, 5730–5737
34. Takano, R.; Misu, T.; Takahashi, T.; Izumiyama, M.; Fujihara, K.; Itoyama, Y. A prominent elevation of glial fibrillary acidic protein in the cerebrospinal fluid during relapse in neuromyelitis optica. Tohoku J. Exp. Med. 2008, 215, 55–59
35. Misu, T.; Takano, R.; Fujihara, K.; Takahashi, T.; Sato, S.; Itoyama, Y. Marked increase in cerebrospinal fluid glial fibrillar acidic protein in neuromyelitis optica: An astrocytic damage marker. J. Neurol. Neurosurg. Psychiatry 2009, 80, 575–577
36. Saadoun, S.; Waters, P.; Bell, B.A.; Vincent, A.; Verkman, A.S.; Papadopoulos, M.C. Intra-cerebral injection of neuromyelitis optica immunoglobulin G and human complement produces neuromyelitis optica lesions in mice. Brain 2010, 133, 349–361
37. Nytrova, P.; Potlukova, E.; Kemlink, D.; Woodhall, M.; Horakova, D.; Waters, P.; Havrdova, E.; Zivorova, D.; Vincent, A.; Trendelenburg, M. Complement activation in patients with neuromyelitis optica. J. Neuroimmunol. 2014, 274, 185–191.
38. Tüzün, E.; Kürtüncü, M.; Türkoğlu, R.; İçöz, S.; Pehlivan, M.; Birişik, Ö.; Eraksoy, M.; Akman-Demir, G. Enhanced complement consumption in neuromyelitis optica and Behcet’s disease patients. J. Neuroimmunol. 2011, 233, 211–215.
39. Kuroda, H.; Fujihara, K.; Takano, R.; Takai, Y.; Takahashi, T.; Misu, T.; Nakashima, I.; Sato, S.; Itoyama, Y.; Aoki, M. Increase of complement fragment C5a in cerebrospinal fluid during exacerbation of neuromyelitis optica. J. Neuroimmunol. 2013, 254, 178–182.
40. Kinoshita, M.; Nakatsuji, Y.; Kimura, T.; Moriya, M.; Takata, K.; Okuno, T.; Kumanogoh, A.; Kajiyama, K.; Yoshikawa, H.; Sakoda, S. Neuromyelitis optica: Passive transfer to rats by human immunoglobulin. Biochem. Biophys. Res. Commun. 2009, 386, 623–627.
41. Jarius, S.; Ruprecht, K.; Wildemann, B.; Kuempfel, T.; Ringelstein, M.; Geis, C.; Kleiter, I.; Kleinschnitz, C.; Berthele, A.; Brettschneider, J.; et al. Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: A multicentre study of 175 patients. J. Neuroinflammation 2012, 9.
42. Jarius, S.; Franciotta, D.; Paul, F.; Ruprecht, K.; Bergamaschi, R.; Rommer, P.S.; Reuss, R.; Probst, C.; Kristoferitsch, W.; Wandinger, K.P.; et al. Cerebrospinal fluid antibodies to aquaporin-4 in neuromyelitis optica and related disorders: Frequency, origin, and diagnostic relevance. J. Neuroinflamm. 2010, 7.
43. Koga, M.; Takahashi, T.; Kawai, M.; Fujihara, K.; Kanda, T. A serological analysis of viral and bacterial infections associated with neuromyelitis optica. J. Neurol. Sci. 2011, 300, 19–22
44. Zhang, E.T.; Inman, C.B.; Weller, R.O. Interrelationships of the pia mater and the perivascular (Virchow–Robin) spaces in the human cerebrum. J. Anat. 1990, 170, 111–123
45. Broadwell, R.D.; Sofroniew, M.V. Serum proteins bypass the blood-brain fluid barriers for extracellular entry to the central nervous system. Exp. Neurol. 1993, 120, 245–263
46. Schlingemann, R.O. Lack of blood–brain barrier properties in microvessels of the prelaminar optic nerve head. Investig. Ophthalmol. Vis. Sci. 2001, 42, 895–901.
47. Bartanusz, V.; Jezova, D.; Alajajian, B.; Digicaylioglu, M. The blood–spinal cord barrier: Morphology and clinical implications. Ann. Neurol. 2011, 70, 194–206.
48. Misu, T.; Fujihara, K.; Kakita, A.; Konno, H.; Nakamura, M.; Watanabe, S.; Takahashi, T.; Nakashima, I.; Takahashi, H.; Itoyama, Y. Loss of aquaporin 4 in lesions of neuromyelitis optica: Distinction from multiple sclerosis. Brain 2007, 130, 1224–1234
49. Waters, P.; Jarius, S.; Littleton, E.; Leite, M.I.; Jacob, S.; Gray, B.; Geraldes, R.; Vale, T.; Jacob, A.; Palace, J.; et al. Aquaporin-4 antibodies in neuromyelitis optica and longitudinally extensive transverse myelitis. Arch. Neurol. 2008, 65, 913–919
50. Paul, F.; Jarius, S.; Aktas, O.; Bluthner, M.; Bauer, O.; Appelhans, H.; Franciotta, D.; Bergamaschi, R.; Littleton, E.; Palace, J.; et al. Antibody to aquaporin 4 in the diagnosis of neuromyelitis optica. PLoS Med. 2007, 4, 669.
51. Hayakawa, S.; Mori, M.; Okuta, A.; Kamegawa, A.; Fujiyoshi, Y.; Yoshiyama, Y.; Mitsuoka, K.; Ishibashi, K.; Sasaki, S.; Hattori, T.; et al. Neuromyelitis optica and anti-aquaporin-4 antibodies measured by an enzyme-linked immunosorbent assay. J. Neuroimmunol. 2008, 196, 181–187.
52. Waters, P.J.; McKeon, A.; Leite, M.I.; Rajasekharan, S.; Lennon, V.A.; Villalobos, A.; Palace, J.; Mandrekar, J.N.; Vincent, A.; Bar-Or, A.; et al. Serologic diagnosis of NMO A multicenter comparison of aquaporin-4-IgG assays. Neurology 2012, 78, 665–671
53. Rash, J.E.; Davidson, K.G.V.; Yasumura, T.; Furman, C.S. Freeze-fracture and immunogold analysis of aquaporin-4 (AQP4) square arrays, with models of AQP4 lattice assembly. Neuroscience 2004, 129, 915–934
54. Hinson, S.R.; McKeon, A.; Fryer, J.P.; Apiwattanakul, M.; Lennon, V.A.; Pittock, S.J. Prediction of neuromyelitis optica attack severity by quantitation of complement-mediated injury to aquaporin-4-expressing cells. Arch. Neurol. 2009, 66, 1164–1167.
55. Watanabe, A.; Matsushita, T.; Doi, H.; Matsuoka, T.; Shigeto, H.; Isobe, N.; Kawano, Y.; Tobimatsu, S.; Kira, J. Multimodality-evoked potential study of anti-aquaporin-4 antibody-positive and-negative multiple sclerosis patients. J. Neurol. Sci. 2009, 281, 34–40.
56. Weinshenker, B.G.; Wingerchuk, D.M.; Vukusic, S.; Linbo, L.; Pittock, S.J.; Lucchinetti, C.F.; Lennon, V.A. Neuromyelitis optica IgG predicts relapse after longitudinally extensive transverse myelitis. Ann. Neurol. 2006, 59, 566–569
57. Melamed, E.; Levy, M.; Waters, P.J.; Sato, D.K.; Bennett, J.L.; John, G.R.; Hooper, D.C.; Saiz, A.; Bar-Or, A.; Kim, H.J.; et al. Update on biomarkers in neuromyelitis optica. Neurol. Neuroimmunol. Neuroinflamm. 2015, 2, e134.
58. Long, Y.; Zheng, Y.; Shan, F.; Chen, M.; Fan, Y.; Zhang, B.; Gao, C.; Gao, Q.; Yang, N. Development of a cell-based assay for the detection of anti-aquaporin 1 antibodies in neuromyelitis optica spectrum disorders. J. Neuroimmunol. 2014, 273, 103–110
59. Tüzün, E.; Tzartos, J.; Ekizoğlu, E.; Stergiou, C.; Zisimopoulou, P.; Çoban, A.; Shugaiv, E.; Türkoğlu, R.; Kürtüncü, M.; Baykan, B.; et al. Aquaporin-1 Antibody in Neuromyelitis Optica Patients. Eur. Neurol. 2014, 72, 271–272.
60. Mader, S.; Gredler, V.; Schanda, K.; Rostasy, K.; Dujmovic, I.; Pfaller, K.; Lutterotti, A.; Jarius, S.; Di Pauli, F.; Kuenz, B.; et al. Complement activating antibodies to myelin oligodendrocyte glycoprotein in neuromyelitis optica and related disorders. J. Neuroinflamm. 2011, 8.
61. Sato, D.K.; Callegaro, D.; Lana-Peixoto, M.A.; Waters, P.J.; de Haidar Jorge, F.M.; Takahashi, T.; Nakashima, I.; Apostolos-Pereira, S.L.; Talim, N.; Simm, R.F.; et al. Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders. Neurology 2014, 82, 474–481.
62. Ramanathan, S.; Reddel, S.W.; Henderson, A.; Parratt, J.D.; Barnett, M.; Gatt, P.N.; Merheb, V.; Kumaran, R.-Y.A.; Pathmanandavel, K.; Sinmaz, N.; et al. Antibodies to myelin oligodendrocyte glycoprotein in bilateral and recurrent optic neuritis. Neurol. Neuroimmunol. Neuroinflamm. 2014, 1, e40.
63. Wingerchuk, D.M.; Weinshenker, B.G. The emerging relationship between neuromyelitis optica and systemic rheumatologic autoimmune disease. Mult. Scler. J. 2012, 18, 5–10.
64. Uzawa, A.; Mori, M.; Arai, K.; Sato, Y.; Hayakawa, S.; Masuda, S.; Taniguchi, J.; Kuwabara, S. Cytokine and chemokine profiles in neuromyelitis optica: Significance of interleukin-6. Mult. Scler. Houndmills Basingstoke Engl. 2010, 16, 1443–1452.
65. Uzawa, A.; Mori, M.; Ito, M.; Uchida, T.; Hayakawa, S.; Masuda, S.; Kuwabara, S. Markedly increased CSF interleukin-6 levels in neuromyelitis optica, but not in multiple sclerosis. J. Neurol. 2009, 256, 2082–2084.
66. Uzawa, A.; Mori, M.; Sawai, S.; Masuda, S.; Muto, M.; Uchida, T.; Ito, S.; Nomura, F.; Kuwabara, S. Cerebrospinal fluid interleukin-6 and glial fibrillary acidic protein levels are increased during initial neuromyelitis optica attacks. Clin. Chim. Acta Int. J. Clin. Chem. 2013, 421, 181–183.
67. Wang, H.; Wang, K.; Zhong, X.; Dai, Y.; Qiu, W.; Wu, A.; Hu, X. Notable increased cerebrospinal fluid levels of soluble interleukin-6 receptors in neuromyelitis optica. Neuroimmunomodulation 2012, 19, 304–308.
68. Uzawa, A.; Mori, M.; Sato, Y.; Masuda, S.; Kuwabara, S. CSF interleukin-6 level predicts recovery from neuromyelitis optica relapse. J. Neurol. Neurosurg. Psychiatry 2012, 83, 339–340
69. Hosokawa, T.; Nakajima, H.; Doi, Y.; Sugino, M.; Kimura, F.; Hanafusa, T.; Takahashi, T. Increased serum matrix metalloproteinase-9 in neuromyelitis optica: Implication of disruption of blood-brain barrier. J. Neuroimmunol. 2011, 236, 81–86.
70. Shimizu, F.; Sano, Y.; Takahashi, T.; Haruki, H.; Saito, K.; Koga, M.; Kanda, T. Sera from neuromyelitis optica patients disrupt the blood-brain barrier. J. Neurol. Neurosurg. Psychiatry 2012, 83, 288–297.
71. Uzawa, A.; Mori, M.; Masuda, S.; Kuwabara, S. Markedly elevated soluble intercellular adhesion molecule 1, soluble vascular cell adhesion molecule 1 levels, and blood-brain barrier breakdown in neuromyelitis optica. Arch. Neurol. 2011, 68, 913–917.
72. McKeon, A.; Lennon, V.A.; Jacob, A.; Matiello, M.; Lucchinetti, C.F.; Kale, N.; Chan, K.H.; Weinshenker, B.G.; Apiwattinakul, M.; Wingerchuk, D.M.; et al. Coexistence of myasthenia gravis and serological markers of neurological autoimmunity in neuromyelitis optica. Muscle Nerve 2009, 39, 87–90.
73. Pittock, S.J.; Lennon, V.A. Aquaporin-4 autoantibodies in a paraneoplastic context. Arch. Neurol. 2008, 65, 629–632.
74. Collongues, N.; de Seze, J. Current and future treatment approaches for neuromyelitis optica. Ther. Adv. Neurol. Disord. 2011, 4, 111–121.
75. Jacob, A.; Matiello, M.; Weinshenker, B.G.; Wingerchuk, D.M.; Lucchinetti, C.; Shuster, E.; Carter, J.; Keegan, B.M.; Kantarci, O.H.; Pittock, S.J. Treatment of neuromyelitis optica with mycophenolate mofetil: Retrospective analysis of 24 patients. Arch. Neurol. 2009, 66, 1128–1133.
76. Weinstock-Guttman, B.; Ramanathan, M.; Lincoff, N.; Napoli, S.Q.; Sharma, J.; Feichter, J.; Bakshi, R. Study of mitoxantrone for the treatment of recurrent neuromyelitis optica (Devic disease). Arch. Neurol. 2006, 63, 957–963.
77. Bakker, J.; Metz, L. Devic’s neuromyelitis optica treated with intravenous gamma globulin (IVIG). Can. J. Neurol. Sci. J. Can. Sci. Neurol. 2004, 31, 265–267.
78. Jacob, A.; Weinshenker, B.G.; Violich, I.; McLinskey, N.; Krupp, L.; Fox, R.J.; Wingerchuk, D.M.; Boggild, M.; Constantinescu, C.S.; Miller, A.; et al. Treatment of neuromyelitis optica with rituximab: Retrospective analysis of 25 patients. Arch. Neurol. 2008, 65, 1443–1448
79. Tradtrantip, L.; Zhang, H.; Saadoun, S.; Phuan, P.-W.; Lam, C.; Papadopoulos, M.C.; Bennett, J.L.; Verkman, A.S. Anti-Aquaporin-4 monoclonal antibody blocker therapy for neuromyelitis optica. Ann. Neurol. 2012, 71, 314–322
80. Pittock, S.J.; Lennon, V.A.; McKeon, A.; Mandrekar, J.; Weinshenker, B.G.; Lucchinetti, C.F.; O’Toole, O.; Wingerchuk, D.M. Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: An open-label pilot study. Lancet Neurol. 2013, 12, 554–562
81. Araki, M.; Matsuoka, T.; Miyamoto, K.; Kusunoki, S.; Okamoto, T.; Murata, M.; Miyake, S.; Aranami, T.; Yamamura, T. Efficacy of the anti-IL-6 receptor antibody tocilizumab in neuromyelitis optica A pilot study. Neurology 2014, 82, 1302–1306.